CARE Series: The Interprofessional Treatment of Pain in the Setting of Substance Use Disorders or Complex Persistent Opioid Dependence

Wednesday, February 4, 2026, 12:00 PM - Sunday, February 4, 2029, 1:00 PM

AMA PRA Category 1 Credits™ (1.00 hours), ANCC Nursing Contact Hours (1.00 hours), CME-Designated Participation Credit (1.00 hours)

Individuals with chronic pain utilizing opioids for pain management may develop complex persistent opioid dependence. Also, a number of individuals with opioid use disorder have co-morbid chronic pain conditions that may respond to opioid analgesia. This didactic presentation will include a review of the incidence of chronic pain with development of complex persistent opioid dependence, opioid-induced hyperalgesia as well as the incidence of chronic pain in those with opioid use disorder. The analgesic management of acute and chronic pain for those individuals on medications for opioid use disorder as well as those with complex persistent opioid dependence will be described utilizing a case-based approach. The presenter will provide recommendations for further education on the management of pain and opioid use disorder to improve clinician competence and will recommend resources for Interprofessional team members to utilize to counsel patients on self-management of pain through nonpharmacologic strategies.

Presenter

Kathleen Broglio, DNP, ANP-BC, ACHPN, CARN-AP, FPCN, FAANP, FAAHPM
Associate Professor of Medicine, Geisel School of Medicine at Dartmouth College 

Kathleen Broglio is an Associate Professor of Medicine at Geisel School of Medicine at Dartmouth College and Nurse Practitioner in Palliative Medicine, Dartmouth Hitchcock Medical Center. She has conducted research on prevalence of opioid misuse risk in oncology; cannabis use in palliative medicine, telehealth during COVID19, and interprofessional palliative care education. Kathleen works with patients with serious illness, complex pain and symptom management needs and substance use disorders. She mentors colleagues, lectures and has published on the treatment of pain in the setting of risks for substance use disorder. Her experience includes acute and chronic pain management; and acute, ambulatory, and home-based palliative care. She is the co-director of the regional Palliative ECHO program which is entering its fifth year.

She received a Bachelors in Economics from University of Maryland, Bachelor of Nursing from University of Hawaii, Masters in Nursing from University of Washington, and Doctorate in Nursing Practice from New York University. She completed a palliative care fellowship at Beth Israel Medical Center, New York.

1. Describe the incidence and complexities associated with chronic pain and comorbid conditions, including complex persistent opioid dependence, opioid-induced hyperalgesia, and opioid use disorder.
2. Discuss strategies for analgesic management of acute and chronic pain in patients with complex persistent opioid dependence, opioid-induced hyperalgesia, and opioid use disorder.
3. Identify resources that support individuals in using self-management strategies to cope with chronic pain.

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Medical Association (AMA)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 ANCC contact hours. 

All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.

2. Register for the activity.

3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.

4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).

5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.

6. Complete and Submit the Evaluation.

Bibliographic Material

• Becker WC, Frank JW, Edmond SN, Starrels JL. When harms outweigh benefits of long-term opioid therapy for pain: Need for a new diagnostic entity, research and improved treatments. Addiction. 2024;119(1):4-5. https://doi.org/10.1111/add.16348

• Benes LL, Keefe FJ, DeBar LL Treating persistent pain: A nurse co-led, interdisciplinary model for primary care. Pain Manage Nurs. 2022;23(6), 728–736. https://doi.org/10.1016/j.pmn.2022.07.004

• Biedlingmaier A, YovankinT, Koola M, Yanuck M, Varghese S. An overview of mindfulness-oriented addiction and pain recovery.  J Nerv Mental Dis, 2022;10(10), 808-810. https://doi.org/10.1097/NMD.0000000000001497.

• Case A, Hansen E, Goforth H, Koob G. The dark side of opioids: The neurobiological cycle of pain, opioids, tapering, hyperkatifeia, and despair. A conversation with George Koob, NIH Addictions Director. J Pain Sym Manage 2022;63(5):840-841. https://doi.org/10.1016/j.jpainsymman.2022.02.31

• Case AA, Kullgren J, Anwar S, Pedraza S, Davis MP. Treating chronic pain with buprenorphine—The practical guide. Curr Treat Options Oncol. 2021;22(12):116–116. *overview of buprenorphine pharmacology and treatment

• Cheatle MD, Giordano NA, Themelis K, Tang NKY. Suicidal thoughts and behaviors in patients with chronic pain, with and without co-occurring opioid use disorder. Pain Med. 2023;24(8):941-948. https://doi.org/10.1093/pm/pnad043

• Coffee Z, Cheng K, Slebodnik, M, Mulligan K, Yu CH, Vanderah TW, Gordon JS. The impact of nonpharmacological interventions on opioid use for chronic noncancer pain: A scoping review. Int. J. Environ. Res. Public Health. 2024; 21(794) https://doi.org/10.3390/ijerph21060794

• DeBar L, Mayhew M, Benes L, et al. A primary care-based cognitive behavioral therapy Intervention for long-term opioid users with chronic pain : A randomized pragmatic Trial. Ann Intern Med. 2022;175(1):46-55. https://doi.org/10.7326/M21-1436

• Fenton JJ, Magnan E, Tseregounis IE, Xing G, Agnoli AL, Tancredi DJ. Long-term risk of overdose or mental health crisis after opioid dose tapering. JAMA Network open.

• Hanley AW, Garland EL. Mindfulness-Oriented Recovery 2022;5(6). https://doi.org/10.1001/jamanetworkopen.2022.16726

• Frimerman L, Verner M, Sirois A, et al. Day-to-day hedonic and calming effects of opioids, opioid craving, and opioid misuse among patients with chronic pain prescribed long-term opioid therapy. Pain. 2021;162(8):2214-2224. https://doi.org/10.1097/j.pain.0000000000002220

• Garland EL, Fix ST, Hudak JP, et al. Mindfulness-Oriented Recovery Enhancement remediates anhedonia in chronic opioid use by enhancing neurophysiological responses during savoring of natural rewards. Psychol Med. 2023;53(5):2085-2094. https://doi.org/10.1017/S0033291721003834

• Garland EL, Hanley AW, Nakamura Y, et al. Mindfulness-Oriented Recovery Enhancement vs supportive group therapy for co-occurring opioid misuse and chronic pain in primary care: A randomized clinical trial. JAMA Intern Med. 2022;182(4):407-417. https://doi.org/10.1001/jamainternmed.2022.0033

• Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. 2020;9(1):41-54. https://doi.org/10.1007/s40122-019-00143-6 *good plain language summary of pharmacology of buprenorphine- open access

• Guichard, L., Hirve, A., Demiri, M., & Martinez, V. (2021). Opioid-induced hyperalgesia in patients with chronic pain: A systematic review of published cases. CliniJ Pain, 38(1), 49–57. https://doi.org/10.1097/AJP.0000000000000994 - good description OIH and treatment strategies

• Jones KF, Broglio K, Ho JJ, Rosa WE. Compassionate care for people with cancer and opioid use disorder. Am J Nurs. 2023;123(8):56-61. https://doi.org/10.1097/01.NAJ.0000947480.74410.06. PMID: 37498041; PMCID: PMC10619200.

• Koob GF. Drug Addiction: Hyperkatifeia/negative reinforcement as a framework for medications development. Pharmacol Rev. 2021;73(1):163-201. https://doi.org/10.1124/pharmrev.120.000083

• Koob GF. Neurobiology of opioid addiction: Opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry. 2020;87(1):44-53. https://doi.org/10.1016/j.biopsych.2019.05.023

• Koob GF. Anhedonia, hyperkatifeia, and negative reinforcement in substance use disorders. Curr Top Behav Neurosci. 2022;58:147-165. https://doi.org/10.1007/7854_2021_288

• Koob GF, Powell P, White A. Addiction as a coping response: Hyperkatifeia, deaths of despair, and COVID-19. Am J Psychiatry. 2020;177(11):1031-1037. https://doi.org/10.1176/appi.ajp.2020.20091375

• Larochelle MR, Lodi S, Yan S, Clothier BA, Goldsmith ES, Bohnert ASB. Comparative effectiveness of opioid tapering or abrupt discontinuation vs no dosage change for opioid overdose or suicide for patients receiving stable long-term opioid therapy. JAMA Network Open. 2022;5(8). https://doi.org/10.1001/jamanetworkopen.2022.26523 data advise against tapering as strategy to prevent OD and suicide

• Manhapra A. Complex persistent opioid dependence—an opioid-induced chronic pain syndrome. Cur Treat Opt Onc. 2022;23(7):921-935. https://doi.org/10.1007/s11864-022-00985-x

• Manhapra A, MacLean RR, Rosenheck R, Becker WC. Are opioids effective analgesics and is physiological opioid dependence benign? Revising current assumptions to effectively manage long-term opioid therapy and its deprescribing. Br J Clin Pharmacol. 2024;90(12):2962-2976. https://doi.org/10.1111/bcp.15972 excellent overview description of problems with LTOT and solutions

• Manhapra A, Sullivan MD, Ballantyne JC, MacLean RR, Becker WC. Complex persistent opioid dependence with long-term opioids: A gray area that needs definition, better understanding, treatment guidance, and policy changes. J Gen Int Medicine; 2020;35(Suppl 3):964-971. https://doi.org/10.1007/s11606-020-06251-w

• Marchette RCN, Vendruscolo LF, Koob GF. The dynorphin/opioid receptor system at the interface of hyperalgesia/hyperkatifeia and addiction. Curr Addict Rep. 2025;12(1):11. https://doi.org/10.1007/s40429-025-00618-x

• Martel MO, Bruneau A, Edwards RR. Mind-body approaches targeting the psychological aspects of opioid use problems in patients with chronic pain: evidence and opportunities. Transl Res. 2021;234:114-128. https://doi.org/10.1016/j.trsl.2021.02.013

• Metz VE, Ray GT, Palzes V, et al. Prescription opioid dose reductions and potential adverse events: a multi-site observational cohort study in diverse US health systems. J Gen Int Med. 2024;39(6):1002-1009. https://doi.org/10.1007/s11606-023-08459-y

• Parisi A, Enhancement reduces opioid craving, pain, and negative affect among chronic pain patients on long-term opioid therapy: An analysis of within- and between-person state effects. Behav Res Ther. 2022;152:104066. https://doi.org/10.1016/j.brat.2022.104066

• Parisi A, Landicho HL, Hudak J, Leknes S, Froeliger B, Garland EL. Emotional distress and pain catastrophizing predict cue-elicited opioid craving among chronic pain patients on long-term opioid therapy. Drug Alcohol Depend. 2022;233:109361. https://doi.org/10.1016/j.drugalcdep.2022.109361

• Parisi A, Taylor-Swanson L, Stewart JL, Khalsa SS, Garland EL. Enhancing interoceptive awareness in chronic pain and opioid misuse via mindfulness-oriented recovery enhancement. Drug Alcohol Depend. 2025;274:112741. https://doi.org/10.1016/j.drugalcdep.2025.112741

• Sampaio-Cunha TJ, Martins I. Knowing the enemy Is halfway towards victory: A scoping review on opioid-induced hyperalgesia. J Clin Med. 2022;11(20), 6161. https://doi.org/10.3390/jcm11206161

• Shurman J, Koob GF, Gutstein HB. Opioids, pain, the brain, and hyperkatifeia: A framework for the rational use of opioids for pain. Pain Med. 2010;11(7):1092-1098. https://doi.org/10.1111/j.1526-4637.2010.00881.x

• St. Marie B, Broglio K. Managing pain in the setting of opioid use disorder. Pain Manage Nurse. 2020;21(1):26-34. https://doi.org/10.1016/j.pmn.2019.08.003.

• Sturgeon JA, Sullivan MD, Parker-Shames S, Tauben D, Coelho P. Outcomes in long-term opioid tapering and buprenorphine transition: A retrospective clinical data analysis. Pain Med. 2020;21(12):3635-3644. https://doi.org/10.1093/pm/pnaa029

• Sullivan MD, Ballantyne JC. Understanding the risks of long-term opioid therapy for chronic pain. Am J Psychiatry. 2022;179(10):696-698. https://doi.org/10.1176/appi.ajp.20220592

• Vogt S, Pfau G, Vielhaber S, Haghikia A, Hachenberg T, Brinkers M. Long-term opioid therapy and mental health comorbidity in patients with chronic pain. Pain Med. 2023;24(7), 837–845. https://doi.org/10.1093/pm/pnad004

• Wilson M, Dolor RJ, Lewis D, Regan SL, Vonder Meulen MB, Winhusen TJ. Opioid dose and pain effects of an online pain self-management program to augment usual care in adults with chronic pain: A multisite randomized clinical trial. Pain, 2023;164(4), 877–885. https://doi.org/10.1097/j.pain.0000000000002785

• Yang Y, Prajapati P, Ramachandran S, et al. Opioid tapering and opioid overdose, opioid use disorder, and mortality among older adults: A nested case-control Study. J Gen Intern Med. 2025;40(12):2896-2905. https://doi.org/10.1007/s11606-025-09492-9

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
ACE Office
Dartmouth Health
[email protected]

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

Dartmouth Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies^.  All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.